Loomis, Sayles & Company’s Verona Pharma VRNA Stock Holding History

Loomis, Sayles & Company’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-177,769	Closed	-$19M	–	758
2025 Q3	$19M	Sell	177,769 -453,940	-72%	-$47.4M	0.02%	251
2025 Q2	$59.7M	Sell	631,709 -164,581	-21%	-$12.2M	0.07%	92
2025 Q1	$50.6M	Sell	796,290 -283,265	-26%	-$16.9M	0.07%	101
2024 Q4	$50.1M	Sell	1,079,555 -31,541	-3%	-$1.18M	0.06%	123
2024 Q3	$32M	Buy	+1,111,096	New	+$27.3M	0.04%	188

Other funds holding VRNA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Loomis, Sayles & Company's VRNA Position: Q4 2025 in Review

Loomis, Sayles & Company sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 177,769 shares — an estimated $19M sold.

Loomis, Sayles & Company first reported a position in VRNA in Q3 2024 and held it in 5 quarters. The position peaked at $59.7M in Q2 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

Loomis, Sayles & Company reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
Loomis, Sayles & Company sold 177,769 Verona Pharma shares in Q4 2025, an estimated $19M.
Loomis, Sayles & Company first reported a position in Verona Pharma in Q3 2024 and held it in 5 quarters.
Loomis, Sayles & Company's Verona Pharma position peaked at $59.7M in Q2 2025.
1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Loomis, Sayles & Company's 13F filing for Q4 2025, filed 12 Feb 2026.